DocDollars

Antares Pharma, Inc.

NJ · United States · Reporting entity ID 100000076367

Total reported 2019–2025
$4.95M
#709 of 2,960 reporting companies — 0% of all reported industry payments
$3.61M in general payments across 111,977 records, plus $1.34M in research funding across 125 records.

How it breaks down

General payments $3,609,902
Research funding $1,336,543

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Antares Pharma, Inc. reported $4.95M to US doctors and teaching hospitals from 2019 to 2025, ranking #709 of 2,960 reporting companies. 27% of that was research funding and 73% general payments such as consulting, speaking, food and travel. 111,977 general payment records and 125 research records were filed.

Common questions about Antares Pharma, Inc.

How much has Antares Pharma, Inc. paid US doctors?

Antares Pharma, Inc. reported $4,946,445 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $3,609,902 in general payments, $1,336,543 in research funding.

How does Antares Pharma, Inc. rank among drug and device companies?

It ranks #709 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Antares Pharma, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.